Table 3 Serum levels of sFlt-1 and PlGF and sFlt-1/PlGF ratio in the subgroups of pre-eclamptic patients

From: Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia

 

Serum sFlt-1 level (pg ml–1)

Serum PlGF level (pg ml–1)

Serum sFlt-1/PlGF ratio

Mild pre-eclampsia (n=35)

6113 (3697–8481)

98.6 (59.3–146)

58.8 (25.6–134)

Severe pre-eclampsia (n=19)

10 269 (5267–15 420)

96.9 (70.1–146)

100 (54.5–198)

Pre-eclampsia without IUGR (n=45)

6689 (3736–12611)

98.9 (68.0–146)

68.6 (31.8–128)

Pre-eclampsia with IUGR (n=9)

8903 (4857–15847)

70.1 (37.6–104)

144 (54.5–422)

Pre-eclampsia with an onset ⩾37 weeks (n=26)

7044 (4498–12720)

116 (91.8–176)

70.5 (32.9–109)

Pre-eclampsia with an onset <37 weeks (n=28)

5631 (3551–11585)

73.3 (41.9–132)

81.6 (24.5–271)

  1. Abbreviations: IUGR, intrauterine growth restriction; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase-1.
  2. Data are presented as median (25–75 percentile).
  3. Significant differences are shown in bold.
Back to article page